Navigation Links
Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital
Date:12/15/2009

SI). Delafloxacin successfully completed two additional Phase 2 trials with the oral formulation. In microbiological tests of large numbers of contemporary clinical isolates of quinolone resistant MRSA, delafloxacin has been shown to be at least 32-fold more potent than levofloxacin, ciprofloxacin, gatifloxacin and moxifloxacin. Delafloxacin also has been shown to be more potent than existing quinolones against a range of Gram-positive, anaerobic, and Gram-negative organisms. Rib-X is currently developing both IV and oral formulations of delafloxacin for use in surgical prophylaxis and other therapeutic areas.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company currently has two drug candidates: delafloxacin, which is ready to enter Phase 3 clinical trials, and radezolid, whose oral form has been tested for safety and efficacy in two Phase 2 trials. Delafloxacin is a broad-spectrum fluoroquinolone with potent activity against quinolone-resistant Gram-positive bacteria, including methicillin-resistant S. aureus (MRSA). Radezolid, a new oxazolidione discovered by Rib-X using its structure-based drug design approach, is an oral/IV agent for the treatment of serious multi-drug-resistant infections. The Company also has two other structure-based discovery programs, Rx-04 and Rx-02. The Rch-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria. The Rx-02 discovery program is focused on developing an IV/oral macrolide active against MRSA, multidrug-resistant Streptococcus pneumoniae, and S. pyogenes. Rib-X's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many know
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Rib-X Pharmaceuticals Expands License Agreement with Yale University on New Ribosome Technology
2. Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
3. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
4. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
6. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
7. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
8. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
9. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
10. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
11. Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Australian biomarker ... important US trial of its MiStat™ prostate cancer screening ... (FDA) regulatory approval upon completion. Minomic,s proprietary ... the presence of a proprietary biomarker known as the ... of prostate cancer cells. Researchers at ...
(Date:9/18/2014)... , Sept. 18, 2014 Relmada Therapeutics, ... for the treatment of chronic pain, announced today that ... to the position of  Senior Director of Clinical Development. ... Mr. James has established and led successful global clinical ... , to facilitate the clinical development of numerous ...
(Date:9/18/2014)... MILFORD, Mass. , Sept. 18, 2014 /PRNewswire/ ... developing novel therapeutics for the treatment of RNA ... National Institutes of Health (NIH) for animal testing ... multiple viral pathogens, classified as "Special Pathogens," against ... SB 9200, derived from Spring Bank,s ...
Breaking Medicine Technology:Minomic Launches US Pilot Study of MiStat(TM) Novel Prostate Cancer Screening Technology 2Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2
... United States Environmental Protection Agency (EPA) announced today a ... will be screened as part of EPA,s ToxCast initiative. ... this year, involves the application of extensive and diverse ... very pleased with our contributions to ToxCast to date, ...
... Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD ) reports ... and Sun Pharma Global, Inc ("Sun Global") for a going ... more of their affiliates would acquire all of the outstanding ... Sun Global for a per share consideration of $4.75 in ...
Cached Medicine Technology:Odyssey Thera to Participate in Expanded EPA Initiative 2Caraco Receives Sun Pharma Proposal to Purchase All Outstanding Shares 2Caraco Receives Sun Pharma Proposal to Purchase All Outstanding Shares 3
(Date:9/18/2014)... Recently, WowBobble.com, the popular online supplier of funny ... to its product line. Moreover, all the company’s products ... customers can enjoy the special offer before September 29, 2014. ... prices ($12.5 for each bobblehead doll ). , ... bobbleheads. We want to make our interesting items available to ...
(Date:9/18/2014)... 18, 2014 Fit Body Boot Camp ... fitness business in the country and its popularity, as both ... to grow enormously in 2014. , The company’s annual ... taking place in Costa Mesa, CA on September 26 and ... conferences yet. Founder Bedros Keuilian, who is also considered the ...
(Date:9/18/2014)... A positive outlook on life can go far ... year, at the Weekend for Women Conference in Los Angeles, ... talk show host Mother Love will be speaking on embracing ... The always-funny Jo Anne Hart, aka Mother Love, has appeared ... widely acclaimed talk show on LATalkRadio.com, which airs weekdays from ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 How much ... That’s one of the factors contributing to the obesity ... constitutes a single serving and how to manage portion ... Control” presentation Oct. 3 at Humility House, 755 Ohltown ... Lackey will lead the informational discussion and answer questions ...
(Date:9/18/2014)... 2014 It is true that ... when building a successful brand or business online. ... has recently compared plenty of professional web hosting ... Arvixe and iPage are the best VPS hosting ... of web hosting. All-sized businesses or enterprises can ...
Breaking Medicine News(10 mins):Health News:Discounted Custom Bobbleheads Online For Sale At WowBobble.com 2Health News:With Fit Body Boot Camp World Conference Nearing, Founder Explains the Fitness Boot Camp Franchise’s Success 2Health News:With Fit Body Boot Camp World Conference Nearing, Founder Explains the Fitness Boot Camp Franchise’s Success 3Health News:DiabetesSisters Showcases Radio Talk Show Host Mother Love at Weekend for Women Conference in Los Angeles 2Health News:HMHP Workshop Addresses Portion Control 2Health News:Best Cheap Hosting USA: GreenGeeks, Arvixe And iPage Are The Best Hosting Suppliers In 2014 2
... , , LOS ANGELES, Dec. ... lives. In a decade, like so many in the preceding century ... been uncounted lives saved . Narconon is certainly ... year out, to save lives. We congratulate the selfless staffs of ...
... working on genetic puzzle to try to save the mammals ... a better understanding of an outbreak of cancerous tumors that ... new report. , Devil facial tumor disease, a kind of ... other physical contact, is one of only two types of ...
... that condition is unavoidable, expert says , THURSDAY, Dec. 31 ... stave off frailty among the elderly. , The notion is ... old that tracked the activities of over 1,000 physically active ... reasonably high-functioning. , Those who spent time volunteering were ...
... ... Online Marketing. We,ve seen a restaurant chain launched promotion that sold out in 90 minutes ... ... downturn of 2009 and closed, there were a handful that took the path less beaten ...
... , WARMINSTER, Pa., Dec. 31 ... leading home gardening company, reports brisk sales for its recently launched, ... containing different varieties for home gardeners who want to make New ... ) , The giant seedpack contains varieties of vegetables and flowers ...
... 31 The following is a statement of Matthew L. ... http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ) , North Carolina on January 2 will ... first major tobacco-growing state to implement a statewide smoke-free law ... will protect the right of North Carolinians to breathe clean ...
Cached Medicine News:Health News:Narconon Salutes Its 1,200 Staff Worldwide on 13,000 Lives Saved This Last Decade 2Health News:Narconon Salutes Its 1,200 Staff Worldwide on 13,000 Lives Saved This Last Decade 3Health News:Clues to Cancer That Could Wipe Out Tasmanian Devils 2Health News:Volunteering May Keep Elderly Stronger 2Health News:Volunteering May Keep Elderly Stronger 3Health News:Small Businesses In Singapore Outmarkets & Outperforms Bigger Players in Tough Economy With Online Marketing 2Health News:New Year's Resolution Garden Growing Sales for Burpee 2Health News:North Carolina Goes Smoke-Free on Jan. 2 in Historic Step for Health 2Health News:North Carolina Goes Smoke-Free on Jan. 2 in Historic Step for Health 3
The Biopro Cox comb cup is manufactured from titanium and is porous coated on the outside of the shell. The Cox comb cup accommodates a polyethylene insert....
The MPF cup is specifically designed to achieve high primary stability, a critical factor for long term success....
The Trilogy system builds on the success of the Harris/Galante Porous and HGP II cups by combining proven features with new technology designed to inhibit the formation and migration of polyethylene ...
For primary and revision cases...
Medicine Products: